SOURCE: MEDX Health Corp.

MedX Health Corp.

July 06, 2015 17:34 ET

MedX Health Corp. Announces Pharmacy Pilot in the United Kingdom

MISSISSAUGA, ON--(Marketwired - July 06, 2015) - MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX) gave an update on recent business developments today, announcing that its European pharmacy-focused channel partner commenced a mole-scanning pilot, using MedX's SIAscopy technology, in 25 Alphega Pharmacies in the United Kingdom.

The mole-scanning service is based on the successful model in place in 100 Norwegian Boots pharmacies, as well as in a Swedish pharmacy chain where the mole-scanning service has recently grown to 32 locations. To date, this mole-scanning service has identified more than 120 life-threatening melanomas.

Alphega Pharmacy is a leading network of independent pharmacists in Europe supporting more than 600 pharmacies in the UK, and 6,500 locations across eight European countries. Alphega is part of the Walgreens Boots Alliance.

"This is a positive development for MedX. We will continue to work with our channel partners to support and grow the pharmacy-based direct to consumer application of our technology," said Rob von der Porten, CEO. We have seen steady sales growth in Q2 and anticipate reporting sound year over year sales gains," he continued.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer; it manufactures and distributes SIMSYS™ and MoleMate™, hand-held devices that use patented technology utilizing light and its remittance to view beneath suspicious moles and lesions in a pain free, non-invasive manner, creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in drugstore settings where the images are sent remotely to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia and Europe. MedX also designs, manufactures and distributes quality low level laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, providing drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation.

These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contact Information

  • For further information:

    Robert von der Porten
    President and CEO
    MedX Health Corp.
    Phone: 905 670 4428